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Abstract
Background: The complete sequencing of the human genome and its subsequent analysis revealed
a predominant role for alternative splicing in the generation of proteome diversity. Splice switching
oligonucleotides (SSOs) are a powerful and specific tool to experimentally control alternative
splicing of endogenous messenger RNAs in living cells. SSOs also have therapeutic potential to treat
diseases that are caused by aberrant splicing. The assignment of biological roles to alternative
splicing events of currently unknown function promises to provide a largely untapped source of
potential new therapeutic targets. Here we have developed a protocol that combines high
sensitivity microarrays with the transfection of SSOs to monitor global changes in gene expression
downstream of alternate, endogenous splice events.
Results: When applied to a well-characterized splicing event in the Bcl-x gene, the application of
high sensitivity microarrays revealed a link between the induction of the Bcl-xS isoform and the
repression of genes involved in protein synthesis.
Conclusion: The strategy introduced herein provides a useful approach to define the biological
impact of any given alternative splicing event on global gene expression patterns. Furthermore, our
data provide the first link between Bcl-xS expression and the repression of ribosomal protein gene
expression.
Background
The completion of the human genome sequence [1,2] and
subsequent analysis of the annotated genome [3] have
revealed that the process of alternative splicing plays a key
role in the generation of proteome diversity. Alternative
splicing decisions control many biological processes rang-
ing from sex determination in fruit flies to programmed
cell death in human cells [4]. Recent estimates suggest that
at least 74% of human genes undergo alternative splicing
[5]. Moreover, a rapidly growing body of evidence shows
that defects in alternative splicing of mRNA are an impor-
tant cause of human disease [6-8]. Strikingly, although
alternative splicing is pervasive within human genes, the
functions of the vast majority of alternative splicing events
remain unknown [3].
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Technical advances in the application of antisense RNA
oligonucleotides to manipulate alternative splicing either
in cultured cells for functional genomic studies, or poten-
tially in patients for therapeutic purposes, are opening
unprecedented avenues to characterize the function of
new alternative splicing events and eventually to exploit
these functions clinically. These splice switching oligonu-
cleotides (SSOs) can be used to induce loss of function or,
when modified to bind cellular proteins, to induce gain of
function by directing splicing regulatory factors to target a
given splicing event [6,8,9].
The use of genome-wide microarrays in conjunction with
SSO is an underutilized but potentially powerful method
to determine the functions of alternative splicing events.
Here we have recorded transcriptome dynamics during
SSO-mediated induction of a well-characterized Bcl-xS
splice variant using high-sensitivity microarrays. The
results reveal a new link between Bcl-xS expression and
the repression of ribosomal protein gene expression.
Methods
Cell culture conditions, molecular biology techniques
and an extensive description of SSO-coupled transcrip-
tome analysis are provided [see Additional file 1].
Results
The Bcl-x gene is alternatively spliced to produce the
major Bcl-xL (long) isoform with anti-apoptotic activity
and a minor Bcl-xS (short) isoform that can promote
apoptosis [10]. A distal alternative 5' splice site (SS) is
used to produce a short Bcl-xS isoform that possesses pro-
apoptotic activity. We chose as a model system the Bcl-x
gene to study downstream effects of inducing the endog-
enous Bcl-xS splice variant because: 1) splice-switching
oligonucleotides were first developed and tested to
enforce splice site selection of the endogenous Bcl-x gene
[11,12], 2) the biological consequences of inducing the
pro-apoptotic Bcl-xS isoform are reasonably well-charac-
terized, and 3) the Bcl-x gene is a potential target for SSO-
based anti-cancer therapies. We used synthetic 2'-O-
methyl-modified oligoribonucleoside phosphorothioate
SSO as previously described by Kole and colleagues
[12,13] to enforce splicing of Bcl-xS as schematised in Fig-
ure 1.
HeLa cervical carcinoma cells were transfected with an
SSO that anneals to the major 5' SS of exon II of the Bcl-x
gene to switch splicing to the minor 5' SS (Bcl-x SSO, Fig-
ure 1). Lipofectamine was selected as the transfection rea-
gent as it has previously been demonstrated to provide
efficient delivery of 2'-O-methyl (2'-O-Me) phospho-
rothioate oligonucleotides into the nucleus of HeLa cells
[14]. The impact of transfection of Bcl-x SSO on the
expression of the alternative Bcl-xS splice variant was ana-
lyzed by RT-PCR with primers flanking the alternative
splicing event. In untreated HeLa cells the levels of Bcl-xS
mRNA were very low (Figure 2A, lane 1). Treatment of
HeLa cells with a control SSO of scrambled sequence did
not alter the levels of Bcl-xS mRNA (Figure 2A, lane 2),
Splice-switching oligonucleotides act on the endogenous Bcl-x gene to enforce splice site choice of the Bcl-xS Figure 1
Splice-switching oligonucleotides act on the endogenous Bcl-x gene to enforce splice site choice of the Bcl-xS. 
The region of the Bcl-x pre-mRNA that includes two alternative 5' splice sites (SSs) that produce either the constitutive long 
(L) splice variant or the alternative short (S) splice variant is schematically depicted. Selection of an intron-proximal L 5' splice 
site (SS) results in production of the Bcl-xL isoform (at right) whereas the selection of the proximal S 5' SS results in the pro-
duction of the Bcl-xS isoform (at left). The SSO oligonucleotide that base pair with the major L splice site forces splicing from 
the distal 5' SS and induces expression of the endogenous Bcl-xS isoform (at left). The Bcl-xL gene product has anti-apoptotic 
activity while the Bcl-xS gene product possesses pro-apoptotic activity.
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indicating the absence of non-specific effects of transfec-
tion of SSOs on Bcl-xS, consistent with previous reports
employing an independent scrambled SSO [12] or 5
nucleotide mismatched SSO [11]. The transfection of the
Bcl-x SSO caused, as previously reported, a strong shift
from the predominant expression of Bcl-xL towards the
expression of Bcl-xS (Figure 2A, lane 3). The levels of
induction of endogenous Bcl-xS by SSO were analyzed
quantitatively by transfection of increasing concentrations
of the Bcl-x SSO into HeLa cells followed by analysis of
the ratio of endogenous Bcl-xS/Bcl-xL+xS mRNA using
Agilent LabChips. The percentage of Bcl-xS/Bcl-xL+xS in
the presence of Bcl-x SSO reached 77% with treatment of
cells with 200 nM SSO and higher concentrations pro-
duced very little further increase in the Bcl-xS/Bcl-xL+xS
ratio (Figure 2B). In contrast, no change in the Bcl-xS/Bcl-
xL+xS ratio was seen with the negative control SSO of ran-
dom sequence at any concentration used (Figure 2B).
Based on the above results we selected treatment with 200
nM Bcl-x SSO as a robust method to enforce splice site
selection of endogenous Bcl-xS for microarray studies.
Treatment of cells with Bcl-xS-inducing SSOs can either
sensitize cells to apoptotic stimuli, or induce apoptosis
outright depending on the cell type and the levels of
expression of Bcl-x [11-13]. In order to correlate changes
in gene expression induced by Bcl-xS expression with the
phenotypic outcome it was important to measure the rates
of apoptosis in our experimental system. To analyze the
impact of shifting the expression of endogenous Bcl-x
from the long to the short isoform on apoptosis, the per-
centage of apoptotic cells was analyzed by flow cytometry
using monoclonal antibodies that detect caspase cleaved
cytokeratin-18, or by measuring Sub G1 DNA content by
staining with propidium iodide. HeLa cells treated with
Bcl-x SSO did not show a statistically significant increase
in levels of apoptosis, in line with the previous results of
Mercatante et al. in HeLa cells [13]. Therefore although
Bcl-xS mRNA expression is strongly induced in HeLa cells,
this change is not accompanied by cell death through
apoptosis.
To study the impact of Bcl-xS induction on gene expres-
sion, we decided to record the downstream transcriptome
dynamics using pan-genomic 60mer oligonucleotide
microarrays and chemiluminescence detection chemistry,
a combination that has previously been shown to provide
increased signal dynamic range and higher sensitivity
when compared to traditional microarray technologies
[15,16]. The microarrays used represent 27,868 fully
annotated and verified human genes. Biologic triplicate
recordings for both control and Bcl-xS SSO transfected
HeLa cells were acquired following total RNA purification
and reverse transcriptase labeling as detailed in the meth-
ods section [see Additional file 1]. After image processing,
Figure 2
Specific control of endogenous Bcl-xS splicing by 
modified antisense RNA oligonucleotides in living 
cells. (A) Antisense RNA oligonucleotide induces endog-
enous Bcl-xS mRNA expression. HeLa cells were transfected 
with 200 nM oligonucleotide directed against the major Bcl-
xL splice site (Bcl-x SSO) or a scrambled control oligonucle-
otide (Control SSO). 24 hours post-transfection total RNA 
was isolated and subjected to RT-PCR with primers that 
amplify both the Bcl-xL and the alternative Bcl-xS mRNAs. 
(B) Concentration-dependent antisense mediated induction 
of Bcl-xS mRNA expression. HeLa cells were transfected 
with antisense RNA oligonucleotides as in A. RT-PCR was 
performed as in A. PCR products were separated by micro-
fluidity and quantified using a 2100 Agilent bioanalyzer. The 
ratio of Bcl-xS mRNA over total Bcl-x mRNA is expressed 
on the y-axis. The values from cells treated with scrambled 
control SSO (open squares), or Bcl-X SSO (black squares) 
are shown. (C) The effect of endogenous Bcl-xS on apoptosis 
in HeLa cells. HeLa cells were transfected as in A. Cells were 
harvested 24 hours post-transfection and percentage of 
apoptotic cells was analyzed by flow cytometry using mono-
clonal antibodies that detect caspase cleaved cytokeratin-18 
(M30; black bars), or by measuring Sub G1 DNA content 
(grey bars). Error bars represent the standard deviation of 
three independent transfections.
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and primary data analysis, we calculated the logarithmic
(base 2) fold-change for all represented genes and deter-
mined their level of statistical significance according to
standard methods. We found a total of 556 genes [see
additional file 2] to be differentially expressed with a p-
value inferior to 0.05 when comparing the transcriptome
from control and Bcl-xS SSO transfected HeLa cells (Fig-
ure 3A &4). Slightly more genes are repressed by Bcl-x SSO
than are induced as 329 or 59% of the genes show a
decrease in expression following splice-site shifting in Bcl-
x. The quality of the transcriptome recordings and their
analysis can be appreciated from comparing the signal
intensities of the least and most induced or repressed
genes (Figure 3B). In the case of the chromosome 3 open-
reading frame 1 as little as a 1.2 fold-change is readily
detected. We then analyzed the differentially expressed
gene list for emergent properties using a meta-analysis of
the available annotation information for statistically sig-
nificant (p < 0.01) over-represented molecular function
and biologic process ontologies. Indeed, for each cate-
gory, two ontologies are highly significantly enriched (Fig-
ure 3C). Note that the molecular function and biologic
process ontologies are not mutually exclusive, quite to the
contrary, the signals in both categories are generated by
essentially the same subset of genes [see Additional files 3,
4, 5 and 6], and point towards a highly relevant enrich-
ment of the protein synthesis apparatus in the Bcl-xS reg-
ulated gene set. Further analysis revealed that the
expression levels of the majority of genes belonging to the
molecular functions singled out through the meta-analy-
sis are reduced following a shift in the cellular equilibrium
towards Bcl-xS (Figure 3D). For example, of 94 genes sig-
nificantly regulated with the molecular function ontology
being ribosomal protein genes, 93 are repressed (Figure
3C &3D). Finally, for a selected number of Bcl-xS targets
we performed independent biological triplicate quantita-
tive RT-PCR analysis to demonstrate reproducibility of
our transcriptome measurements with an independent
technology (Figure 3E). As expected, the qPCR results con-
firm the microarray data for all tested genes (Figure 3E).
The Pearson correlation coefficient for the correlation
between the microarray data and the qPCR is 0.872, pro-
viding a statistical measure that reinforces the validity of
the microarray data. We therefore have demonstrated the
feasibility of using high sensitivity transcriptome analysis
as a tool for defining the outcome of alternative splicing
events on global gene expression patterns.
Conclusion
Here we have combined splice-switching oligonucleotides
(SSOs) with high-sensitivity genome-wide microarrays to
reveal the impact of shifting the expression of the endog-
enous Bcl-xL splice variant towards the Bcl-xS splice vari-
ant. To our knowledge, only a single study attempted to
address the impact of SSO on gene expression patterns
using microarrays [17]. In that study, no statistically sig-
nificant impact of Bcl-xS SSO on specific cellular func-
tions or pathways was uncovered. Here we demonstrate a
statistically significant impact of Bcl-xS SSOs on the
repression of ribosomal protein-encoding genes and
genes that code for nucleic acid binding proteins. Several
factors could contribute to the different outcome of our
study when compared to the earlier study [17]. For exam-
ple, different cell lines can give different transcriptome
footprints, and we have employed HeLa whereas Mercat-
ante et al. employed MCF7 and PC3 cells. Moreover the
time of SSO treatment in our study was 18 hours versus 36
hours in that of Mercatante et al., a difference that could
influence the number of primary versus secondary effects
of the SSO. Here we have combined for the first time SSO
with second-generation microarrays that possess substan-
tially increased sensitivity and genome coverage and thus
provide improved detection of statistically significant
changes in specific gene ontologies. The capacity to detect
specific cellular pathways that are impacted upon SSO
represents an advance that can provide new biological
insights into the function of alternative splicing events.
Our study has focused on the transcriptome signature
induced by Bcl-x SSO in the HeLa cell model system, how-
ever the methodology we describe should also be applica-
ble to any alternative splicing event in any cell line that
responds efficiently to SSO transfection. Genome-wide
technologies have revealed the pervasive role of alterna-
tive splicing in proteome diversity, yet the functions of the
vast majority of splice variants remain unknown [3]. The
merging of SSO and second-generation microarray tech-
nology that we present here provides a powerful and
broadly applicable methodology to decipher the biologi-
cal functions that are controlled by alternative splicing
events.
The transcriptome footprint caused by the induction of
endogenous Bcl-xS results in a dramatic suppression of
genes involved in protein synthesis, particularly ribos-
omal protein encoding genes (Figure 3C). Since we do not
observe a strong apoptotic response in cells treated with
Bcl-x SSO (Figure 2C), we conclude that the measured
decreases in the expression of genes related to protein syn-
thesis cannot alone induce apoptosis. Bcl-xS has been
characterized as a pro-apoptotic factor that is localized
largely to the mitochondria [18]. An impact of Bcl-xS-
inducing SSO on the suppression of genes that participate
in protein synthesis was therefore an unanticipated out-
come. Boone-Unge and colleagues [19] have recently
reported a biological link between the inhibition of pro-
tein translation and Bcl-xS using a completely unrelated
approach. Their data showed that the translational inhib-
itor emitine causes a significant increase in the cellular lev-
els of Bcl-xS mRNA. It is therefore conceivable that a
feedback loop between Bcl-xS expression and transla-BMC Research Notes 2008, 1:94 http://www.biomedcentral.com/1756-0500/1/94
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Figure 3 (see legend on next page)
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tional inhibition exists. Further work will be required to
confirm the hypothesis of such a feedback mechanism.
In summary, we report here a protocol that enables the
measurement of the impact of endogenous alternative
splicing events on transcriptome dynamics. When applied
to the induction of Bcl-xS mRNA by splice-switching oli-
gonucleotides we demonstrate a statistically significant
suppression of ribosomal protein encoding genes. The
approach applied here should accelerate efforts to define
the biological roles of the vast numbers of uncharacter-
ized alternative splice variants within the human genome.
Finally, the approach we describe can also be applied to
the analysis of the mechanism of action of clinically use-
ful SSOs.
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Endogenous Bcl-xS expression orchestrates a cellular gene expression program linked to the protein synthesis machinery Figure 3 (see previous page)
Endogenous Bcl-xS expression orchestrates a cellular gene expression program linked to the protein synthesis 
machinery. (A) Transcriptome analysis following Bcl-x SSO in HeLa cells. Expression levels of mRNAs from Bcl-x AS-treated 
cells were compared to control oligonucleotide-treated HeLa samples 18 hours post SSO transfection by genome-wide micro-
array analysis using three independent biologic replicates each. The absolute number of probes detecting statistically significant 
(p < 0.05) up- or down-regulation following splice-site selection is shown to the left of the bar; the maximum positive or nega-
tive logarithmic (base two) fold-change is shown to the right. The black gradient indicates positive, and the white gradient neg-
ative fold changes in expression. (B) The relative, normalized, averaged chemiluminescence signal intensities for the least 
repressed (C3orf1), the least induced (GNA11), the most repressed ("-"; no annotation information available), and the most 
induced (MGC48628) gene when comparing the Bcl-x AS oligonucleotide (black bars) to the control AS oligonucleotide (grey 
bars) at a statistical significance threshold of p < 0.05 as well as the standard deviations over those signals are compared. (C) 
Specific biologic processes and molecular functions are statistically significantly (p < 0.01) overrepresented in the Bcl-xS-tran-
scriptome. "Count" indicates the number of probes within the Bcl-x dataset that can be attributed to the corresponding ontol-
ogy term, "Expected" is the number of probes one would expect to find for a given ontology term in a random dataset of 
identical size. (D) Pie-chart analysis of genes down-regulated by endogenous Bcl-xS SSO illustrating the number of genes asso-
ciated with the ontology term "molecular function: Ribosomal Protein" (grey), and "molecular function: Nucleic Acid Binding" 
(black) as a fraction of all genes down-regulated by endogenous Bcl-xS SSO. (E) Verification of gene expression changes by 
quantitative real-time RT-PCR. HeLa cells were transfected with antisense oligonucleotides that induce endogenous Bcl-xS 
expression. 18 hours post-transfection total RNA was isolated from cells and expression level changes were analyzed by quan-
titative real-time PCR (grey bars) and compared with changes in expression from microarray measurements (black bars) as log-
arithmic base-two fold changes. Error bars indicate standard deviation of three independent transfections. The Pearson 
correlation coefficient calculated for the correlation between the microarray data and the qPCR is 0.872.BMC Research Notes 2008, 1:94 http://www.biomedcentral.com/1756-0500/1/94
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Transcriptome analysis Figure 4
Transcriptome analysis. (A) A Heat-map for the Bcl-x AS versus control AS subtraction profile is shown. Note that the 
non-normalized signal intensities for the probes revealing statistically significant changes in gene expression (p < 0.05) are rep-
resented by a black (low signal) to green (high signal) gradient. The probes are ordered in a logarithmic (base-two) fold-change 
descending order ("log2(FC)") which is displayed as a red (highly up-regulated) to black to blue (highly down-regulated) gradi-
ent. (B) A color code legend for the data displayed in (A) is given.
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0500-1-94-S5.txt]
Additional file 6
An ascii tab-delimited file is provided containing the listing of the probe 
IDs (PROBE), the log2 fold-changes (LOG_Q), the log2 fold change esti-
mated variance (VAR), the P-value (P), as well as several gene identifi-
ers, for the subset of selected probes mapping to the Ribosomal Protein 
ontology term used for the meta-analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
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